Polar Capital’s BeOne Medicines Ltd ONC Stock Holding History

Polar Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-100,000	Closed	-$13.2M	–	304
2019 Q1	$13.2M	Sell	100,000 -60,000	-38%	-$8.1M	0.12%	169
2018 Q4	$22.4M	Buy	160,000 +75,000	+88%	+$9.95M	0.24%	127
2018 Q3	$14.6M	Buy	85,000 +10,000	+13%	+$1.68M	0.12%	165
2018 Q2	$11.5M	Buy	75,000 +25,000	+50%	+$4.46M	0.07%	186
2018 Q1	$8.4M	Sell	50,000 -30,000	-38%	-$4.06M	0.08%	196
2017 Q4	$7.82M	Buy	80,000 +5,000	+7%	+$458K	0.08%	180
2017 Q3	$7.76M	Sell	75,000 -25,000	-25%	-$1.86M	0.09%	182
2017 Q2	$4.5M	Hold	100,000	–	–	0.06%	196
2017 Q1	$3.66M	Buy	100,000 +40,000	+67%	+$1.46M	0.05%	202
2016 Q4	$1.82M	Buy	+60,000	New	+$1.89M	0.03%	235

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Polar Capital's ONC Position: Q2 2019 in Review

Polar Capital sold out of BeOne Medicines Ltd (ONC) in Q2 2019, closing a stake of 100,000 shares — an estimated $13.2M sold.

Polar Capital first reported a position in ONC in Q4 2016 and held it in 10 quarters. The position peaked at $22.4M in Q4 2018. 203 funds tracked by Wall St. Rank hold ONC as of Q2 2019.

Polar Capital reported no remaining BeOne Medicines Ltd position as of Q2 2019 after selling out during the quarter.
Polar Capital sold 100,000 BeOne Medicines Ltd shares in Q2 2019, an estimated $13.2M.
Polar Capital first reported a position in BeOne Medicines Ltd in Q4 2016 and held it in 10 quarters.
Polar Capital's BeOne Medicines Ltd position peaked at $22.4M in Q4 2018.
203 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2019.

Based on Polar Capital's 13F filing for Q2 2019, filed 14 Aug 2019.